Literature DB >> 2995843

Dopaminergic modulation of hippocampal noradrenaline release. Evidence for alpha 2-antagonistic effects of some dopamine receptor agonists and antagonists.

R Jackisch, S Moll, T J Feuerstein, G Hertting.   

Abstract

3H-Noradrenaline release in the rabbit hippocampus and its possible modulation via presynaptic dopamine receptors was studied. Hippocampal slices were preincubated with 3H-noradrenaline, continuously superfused in the presence of cocaine (30 mumol/l) and subjected to electrical field stimulation. The electrically evoked tritium overflow from the slices was reduced by 0.1 and 1 mumol/l dopamine and apomorphine, but significantly enhanced by 10 mumol/l apomorphine or by 0.1 and 1 mumol/l bromocriptine. If the alpha 2-adrenoceptor antagonist yohimbine (0.1 mumol/l) was present throughout superfusion, the inhibitory effects of dopamine and apomorphine were more pronounced and even 10 mumol/l apomorphine and 1 mumol/l bromocriptine inhibited noradrenaline release. Qualitatively similar observations were made in the presence of another alpha 2-antagonist, idazoxane (0.1 mumol/l). In the presence of the D2-receptor antagonist domperidone (0.1 mumol/l) the inhibitory effects of dopamine were almost abolished, whereas both apomorphine (greater than 1 mumol/l) and bromocriptine (greater than 0.01 mumol/l) greatly facilitated noradrenaline release. The D2-receptor agonist LY 171555 (0.1 and 1 mumol/l) significantly reduced the evoked noradrenaline release whereas the D1-selective agonist SK & F 38393 was ineffective at similar concentrations. The effects of LY 171555 were abolished in the presence of domperidone (0.1 mumol/l) but remained unchanged in the presence of yohimbine or idazoxane (0.1 mumol/l, each). At 1 mumol/l the D2-receptor antagonists domperidone and (-)sulpiride significantly increased the evoked noradrenaline release by about 10%. However, at this concentration, domperidone (but not (-)sulpiride) affected also basal tritium outflow. Bulbocapnine and the preferential D1-receptor antagonists SCH 23390 enhanced the evoked noradrenaline release already at 0.1 mumol/l.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2995843     DOI: 10.1007/bf00499902

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  36 in total

Review 1.  Localization of transmitter candidates in the brain: the hippocampal formation as a model.

Authors:  J Storm-Mathisen
Journal:  Prog Neurobiol       Date:  1977       Impact factor: 11.685

2.  Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain.

Authors:  S J Peroutka; D C U'Prichard; D A Greenberg; S H Snyder
Journal:  Neuropharmacology       Date:  1977-09       Impact factor: 5.250

3.  5HT-receptor antagonist properties of SCH 23390 in vascular smooth muscle and brain.

Authors:  P E Hicks; H Schoemaker; S Z Langer
Journal:  Eur J Pharmacol       Date:  1984-10-15       Impact factor: 4.432

Review 4.  Two dopamine receptors: biochemistry, physiology and pharmacology.

Authors:  J C Stoof; J W Kebabian
Journal:  Life Sci       Date:  1984-12-03       Impact factor: 5.037

5.  Activity of two new potent dopaminergic agonists at the striatal and anterior pituitary levels.

Authors:  C Euvrard; L Ferland; T Di Paolo; M Beaulieu; F Labrie; C Oberlander; J P Raynaud; J R Boissier
Journal:  Neuropharmacology       Date:  1980-04       Impact factor: 5.250

6.  alpha-Adrenoceptor-mediated inhibition of noradrenaline release in rabbit brain cortex slices. Receptor properties and role of the biophase concentration of noradrenaline.

Authors:  D Reichenbacher; W Reimann; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-04       Impact factor: 3.000

7.  Preferential inhibition of ligand binding to calf striatal dopamine D1 receptors by SCH 23390.

Authors:  A J Cross; R D Mashal; J A Johnson; F Owen
Journal:  Neuropharmacology       Date:  1983-11       Impact factor: 5.250

8.  Evidence for dopamine as a transmitter in dorsal hippocampus.

Authors:  K Ishikawa; T Ott; J L McGaugh
Journal:  Brain Res       Date:  1982-01-28       Impact factor: 3.252

9.  Further functional in vitro comparison of pre- and postsynaptic dopamine receptors in the rabbit caudate nucleus.

Authors:  K Starke; L Späth; J D Lang; C Adelung
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-08       Impact factor: 3.000

10.  Endogenous noradrenaline as modulator of hippocampal serotonin (5-HT)-release. Dual effects of yohimbine, rauwolscine and corynanthine as alpha-adrenoceptor antagonists and 5-HT-receptor agonists.

Authors:  T J Feuerstein; G Hertting; R Jackisch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-05       Impact factor: 3.000

View more
  6 in total

1.  Opposing role of dopamine D1 and D2 receptors in modulation of rat nucleus accumbens noradrenaline release.

Authors:  L J Vanderschuren; G Wardeh; T J De Vries; A H Mulder; A N Schoffelmeer
Journal:  J Neurosci       Date:  1999-05-15       Impact factor: 6.167

2.  Effect of corticosterone on noradrenergic nuclei in the pons-medulla and [3H]NA release from terminals in hippocampal slices.

Authors:  A S de Villiers; V A Russell; J J Taljaard
Journal:  Neurochem Res       Date:  1992-03       Impact factor: 3.996

3.  The adenosine receptor-mediated inhibition of noradrenaline release possibly involves an N-protein and is increased by alpha 2-autoreceptor blockade.

Authors:  C Allgaier; G Hertting; O V Kügelgen
Journal:  Br J Pharmacol       Date:  1987-02       Impact factor: 8.739

4.  False labelling of dopaminergic terminals in the rabbit caudate nucleus: uptake and release of [3H]-5-hydroxytryptamine.

Authors:  T J Feuerstein; G Hertting; A Lupp; B Neufang
Journal:  Br J Pharmacol       Date:  1986-07       Impact factor: 8.739

5.  Functional regulation by dopamine receptors of serotonin release from the rat hippocampus: in vivo microdialysis study.

Authors:  M Matsumoto; M Yoshioka; H Togashi; T Ikeda; H Saito
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-05       Impact factor: 3.000

6.  Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic target of bromocriptine.

Authors:  Despoina Aslanoglou; Suzanne Bertera; Laura Friggeri; Marta Sánchez-Soto; Jeongkyung Lee; Xiangning Xue; Ryan W Logan; J Robert Lane; Vijay K Yechoor; Peter J McCormick; Jens Meiler; R Benjamin Free; David R Sibley; Rita Bottino; Zachary Freyberg
Journal:  iScience       Date:  2022-07-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.